Revolution Medicines' daraxonrasib Phase 3 trial meets OS endpoint: 13.2 vs 6.7 months, HR 0.40

Revolution Medicines, Inc.

Phase 3 RASolute 302 trial: median OS 13.2 mo vs 6.7 mo for chemo (HR 0.40, p<0.0001); PFS also statistically significant.
Daraxonrasib generally well tolerated with manageable safety profile; no new safety signals.
Trial results considered final from first interim analysis; company to submit to FDA and other global regulators.
Data to support future NDA via a Commissioner’s National Priority Voucher.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.